On June 8, Alibaba Health fell 3.34% in regular trading, trading at HKD 3.47 per share, with trading volume of HKD 130 million, extending its post-earnings downtrend.

On the news front, the National Medical Products Administration recently issued new compliance guidelines for online prescription drug sales, explicitly prohibiting AI from replacing licensed pharmacists in prescription review, restricting promotional activities for prescription drugs, and banning livestream-induced medication use. These measures are expected to increase platform compliance costs and pressure short-term profitability for pharmaceutical e-commerce players.

Additionally, major investment banks including Goldman Sachs and Jefferies recently lowered their target prices for Alibaba Health following its fiscal year results released on May 14, reflecting concerns over slowing revenue growth. Goldman Sachs cut its target to HKD 4.2 while maintaining a neutral rating, and Jefferies lowered its target to HKD 5.3 while reiterating a buy rating.

Within the Internet and Direct Marketing Retail sector, the overall sector declined broadly. Among individual stocks, BABA-W down 3.59%, Meituan-W down 4.50%, JD-SW down 2.42%, JD Health down 2.74%, PA Good Doctor down 2.74%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)